
USD
+$0.00
(+0.00%
)At Close (As of Dec 12, 2025)
$2.81B
Market Cap
-
P/E Ratio
-2.05
EPS
$48.45
52 Week High
$16.50
52 Week Low
HEALTHCARE
Sector
| Field | Value (CNY) |
|---|---|
| Gross Profit | $952M |
| Total Revenue | $981M |
| Cost Of Revenue | $29M |
| Costof Goods And Services Sold | $29M |
| Operating Income | -$370M |
| Selling General And Administrative | $187M |
| Research And Development | $947M |
| Operating Expenses | $1.3B |
| Investment Income Net | - |
| Net Interest Income | -$27M |
| Interest Income | $38M |
| Interest Expense | $64M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $93M |
| Income Before Tax | -$395M |
| Income Tax Expense | $10M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$406M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$331M |
| Ebitda | -$238M |
| Net Income | -$405M |
| Field | Value (CNY) |
|---|---|
| Total Assets | $2.6B |
| Total Current Assets | $1.5B |
| Cash And Cash Equivalents At Carrying Value | $1.2B |
| Cash And Short Term Investments | $1.2B |
| Inventory | $6.6M |
| Current Net Receivables | $99M |
| Total Non Current Assets | $1.1B |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | $76M |
| Intangible Assets Excluding Goodwill | $76M |
| Goodwill | $25M |
| Investments | - |
| Long Term Investments | $34M |
| Short Term Investments | $5.4M |
| Other Current Assets | $132M |
| Other Non Current Assets | - |
| Total Liabilities | $2.3B |
| Total Current Liabilities | $1.2B |
| Current Accounts Payable | $92M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $779M |
| Total Non Current Liabilities | $1.2B |
| Capital Lease Obligations | $30M |
| Long Term Debt | $869M |
| Current Long Term Debt | $770M |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $1.7B |
| Other Current Liabilities | $232M |
| Other Non Current Liabilities | $6.3M |
| Total Shareholder Equity | $264M |
| Treasury Stock | - |
| Retained Earnings | -$5.8B |
| Common Stock | $214K |
| Common Stock Shares Outstanding | $302M |
| Field | Value (CNY) |
|---|---|
| Operating Cashflow | -$111M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $93M |
| Capital Expenditures | $24M |
| Change In Receivables | - |
| Change In Inventory | $9.6M |
| Profit Loss | - |
| Cashflow From Investment | -$362M |
| Cashflow From Financing | $315M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | $0 |
| Dividend Payout Common Stock | $0 |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | $0 |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$395M |
| Field | Value (CNY) |
|---|---|
| Gross Profit | $952M |
| Total Revenue | $981M |
| Cost Of Revenue | $29M |
| Costof Goods And Services Sold | $29M |
| Operating Income | -$370M |
| Selling General And Administrative | $187M |
| Research And Development | $947M |
| Operating Expenses | $1.3B |
| Investment Income Net | - |
| Net Interest Income | -$27M |
| Interest Income | $38M |
| Interest Expense | $64M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $93M |
| Income Before Tax | -$395M |
| Income Tax Expense | $10M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$406M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$331M |
| Ebitda | -$238M |
| Net Income | -$405M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Ascentage Pharma Group International (AAPG) is a pioneering clinical-stage biotechnology firm headquartered in Suzhou, China, dedicated to the development of transformative therapies for cancer, chronic hepatitis B virus (HBV), and age-related diseases. Leveraging proprietary drug discovery technologies, Ascentage seeks to address critical unmet medical needs, making significant contributions to oncology and infectious disease treatment. With a robust pipeline and a commitment to innovation, the company is strategically positioned to capitalize on growth opportunities within the dynamic biotechnology sector both in China and globally.